Table 4 Bivariate and multivariate analyses factors associated with adherence to AL among uncomplicated P. falciparum malaria patients in AsgedeTsimbla district, Tigray, Ethiopia, 2018 (n = 384)
Variable | Adherence to AL | COR (95%CI) | P-value | AOR (95%CI) | P-value | ||
|---|---|---|---|---|---|---|---|
Non-adhered n (%) | Adhered n (%) | ||||||
Age group (years) | < 5 | 27 (15.2) | 69 (33.5) | 0.3 (0.1–0.52) | 0.01 | 0.4 (0.2–0.88) | 0.02* |
5 to 17 | 44 (24.7) | 52 (25.2) | 0.6 (0.4–1.1) | 0.11 | 0.7 (0.3–1.41) | 0.74 | |
≥ 18 | 107 (60.1) | 85 (41.3) | 1 | 1 | |||
Educational level | Illiterate | 108 (60.7) | 53 (25.7) | 15 (7.5–29.7) | 0.01 | 9.4 (4.2–21.3) | 0.01** |
Primary (1–8 grade) | 58 (32.6) | 65 (31.6) | 6.5 (3.2–13.1) | 0.01 | 4.5 (1.9–10.2) | 0.01** | |
Secondary and above | 12 (6.7) | 88 (42.7) | 1 | 1 | |||
Had radio/TV | No | 86 (48.3) | 72 (35) | 1.7 (1.1–2.6) | 0.01 | 0.8 (0.4–1.5) | 0.5 |
Yes | 92 (51.7) | 134 (65) | 1 | 1 | |||
Treatment given | Health post | 56 (31.5) | 106 (51.5) | 0.4 (0.2–0.65) | 0.01 | 0.3 (0.1–0.55) | 0.01** |
Health center | 122 (68.5) | 100 (48.5) | 1 | 1 | |||
Improved during visit | No | 6 (3.4) | 12 (6) | 0.5 (0.2–1.5) | 0.26 | 0.9 (0.2–3.4) | 0.87 |
Yes | 172 (96.6) | 194 (94) | 1 | 1 | |||
Recalled side effect | No | 160 (90) | 144 (70) | 3.8 (2.1–6.7) | 0.01 | 1.1 (0.4–2.5) | 0.8 |
Yes | 18 (10) | 62 (30) | 1 | 1 | |||
Knew consequences of AL discontinued | No | 174 (84.5) | 78 (43.8) | 6.9 (4.3–11.2) | 0.01 | 4.0 (2.1–7.6) | 0.01** |
Yes | 32 (15.5) | 100 (56.2) | 1 | 1 | |||
Had AL bitter taste | No | 64 (36) | 118 (57.3) | 0.7 (0.4–1.0) | 0.08 | 0.8 (0.4–1.4) | 0.5 |
Yes | 114 (64) | 88 (42.3) | 1 | 1 | |||
Vomited within 30 min of ingestion | Waited till the next dose | 112 (62.9) | 76 (36.9) | 2.9 (1.9–4.3) | 0.01 | 1.0 (0.5–1.9) | 0.92 |
Repeated the dose | 66 (37.1) | 130(63.1) | 1 | 1 | |||
Improved before tablets got finished | Stopped/saved drug | 111 (62.4) | 35 (17) | 8.1 (5.0–13) | 0.01 | 3.2 (1.7–5.9) | 0.01** |
Continued till finished | 67 (37.6) | 171 (83) | 1 | 1 | |||
Perceived preferred drug formulation | Syrup | 57 (32) | 34 (16.5) | 3.6 (2.1–6.1) | 0.01 | 1.8 (0.9–4.2) | 0.06 |
Injection | 67 (37.6) | 55 (26.7) | 2.6 (1.6–4.2) | 0.01 | 2 (0.9–4.2) | 0.06 | |
Tablets | 54 (30.4) | 117 (56.8) | 1 | 1 | |||
Concomitant drugs | Yes | 98 (55) | 47 (22.8) | 4.1 (2.6–6.4) | 0.01 | 2.5 (1.4–4.5) | 0.01** |
No | 80 (45) | 159 (77.2) | 1 | 1 | |||
First dose taken | At home | 158 (88.8) | 168 (81.6) | 1.7 (0.9–3.2) | 0.05 | 0.5 (0.2–1.2) | 0.13 |
At health facility | 20 (11.2) | 38 (18.4) | 1 | 1 | |||
Prescribed drug instruction given | Package as visual aid | 82 (46.1) | 102 (49.5) | 0.7 (0.4–1.0) | 0.11 | 1.0 (0.3–3.1) | 0.87 |
Verbal with written | 12 (6.7) | 30 (14.6) | 0.3 (0.1–0.73) | 0.01 | 2 (0.7–5.9) | 0.16 | |
Verbal only | 84 (47.2) | 74 (35.9) | 1 | 1 | |||
Got chance to repeat prescription instruction | No | 151 (84.8) | 134 (65) | 3 (1.8–4.9) | 0.12 | 1.8 (0.9–3.6) | 0.06 |
Yes | 27 (15.2) | 72 (35) | 1 | 1 | |||